Ghent University Academic Bibliography

Advanced

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

Vanessa Smith UGent, JENS VAN PRAET UGent, BERNARD VANDOOREN UGent, Bert Van der Cruyssen, J.-M. Naeyaert, Saskia Decuman UGent, Dirk Elewaut UGent and Filip De Keyser UGent (2010) ANNALS OF THE RHEUMATIC DISEASES. 69(1). p.193-197
abstract
Objectives: The safety and potential efficacy of rituximab was examined in diffuse cutaneous systemic sclerosis (dc-SSc). Methods: A 24 week open-label study in which eight patients with dc-SSc received an infusion of 1000 mg rituximab administered at baseline and day 15, together with 100 mg methylprednisolone at each infusion. Assessment included CD19+ peripheral blood lymphocyte number, skin sclerosis score, indices of internal organ functioning, the health assessment questionnaire disability index, the 36-item Short Form health survey and histopathological evaluation of the skin. Results: Ritixumab induced effective B-cell depletion in all patients (, 5 CD19+ cells/ml blood). There was a significant change in skin score at week 24 (p<0.001). Also, significant improvements were measured in the dermal hyalinised collagen content (p = 0.014) and dermal myofibroblast numbers (p = 0.011). Two serious adverse events occurred, which were thought to be unrelated to the rituximab treatment. Conclusions: Rituximab appears to be well tolerated and may have potential efficacy for skin disease in dc-SSc. This study is registered with ClinicalTrials.gov, number NCT00379431.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
keyword
DISEASE, SCLERODERMA RENAL CRISIS, OUTCOMES, TRIAL, MULTICENTER
journal title
ANNALS OF THE RHEUMATIC DISEASES
Ann. Rheum. Dis.
volume
69
issue
1
pages
5 pages
publisher
B M J PUBLISHING GROUP
place of publication
LONDON
Web of Science type
Article
Web of Science id
000272594100034
JCR category
RHEUMATOLOGY
JCR impact factor
9.082 (2010)
JCR rank
1/29 (2010)
JCR quartile
1 (2010)
ISSN
0003-4967
DOI
10.1136/ard.2008.095463
language
English
UGent publication?
yes
classification
A1
id
851481
handle
http://hdl.handle.net/1854/LU-851481
date created
2010-02-04 12:07:39
date last changed
2010-02-17 14:08:27
@article{851481,
  abstract     = {Objectives: The safety and potential efficacy of rituximab was examined in diffuse cutaneous systemic sclerosis (dc-SSc).

Methods: A 24 week open-label study in which eight patients with dc-SSc received an infusion of 1000 mg rituximab administered at baseline and day 15, together with 100 mg methylprednisolone at each infusion. Assessment included CD19+ peripheral blood lymphocyte number, skin sclerosis score, indices of internal organ functioning, the health assessment questionnaire disability index, the 36-item Short Form health survey and histopathological evaluation of the skin.

Results: Ritixumab induced effective B-cell depletion in all patients (, 5 CD19+ cells/ml blood). There was a significant change in skin score at week 24 (p{\textlangle}0.001). Also, significant improvements were measured in the dermal hyalinised collagen content (p = 0.014) and dermal myofibroblast numbers (p = 0.011). Two serious adverse events occurred, which were thought to be unrelated to the rituximab treatment.

Conclusions: Rituximab appears to be well tolerated and may have potential efficacy for skin disease in dc-SSc. This study is registered with ClinicalTrials.gov, number NCT00379431.},
  author       = {Smith, Vanessa and VAN PRAET, JENS and VANDOOREN, BERNARD and Van der Cruyssen, Bert and Naeyaert, J.-M. and Decuman, Saskia and Elewaut, Dirk and De Keyser, Filip},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  keyword      = {DISEASE,SCLERODERMA RENAL CRISIS,OUTCOMES,TRIAL,MULTICENTER},
  language     = {eng},
  number       = {1},
  pages        = {193--197},
  publisher    = {B M J PUBLISHING GROUP},
  title        = {Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study},
  url          = {http://dx.doi.org/10.1136/ard.2008.095463},
  volume       = {69},
  year         = {2010},
}

Chicago
SMITH, VANESSA, JENS VAN PRAET, BERNARD VANDOOREN, Bert Van der Cruyssen, J.-M. Naeyaert, Saskia Decuman, Dirk Elewaut, and Filip De Keyser. 2010. “Rituximab in Diffuse Cutaneous Systemic Sclerosis: An Open-label Clinical and Histopathological Study.” Annals of the Rheumatic Diseases 69 (1): 193–197.
APA
SMITH, V., VAN PRAET, J., VANDOOREN, B., Van der Cruyssen, B., Naeyaert, J.-M., Decuman, S., Elewaut, D., et al. (2010). Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. ANNALS OF THE RHEUMATIC DISEASES, 69(1), 193–197.
Vancouver
1.
SMITH V, VAN PRAET J, VANDOOREN B, Van der Cruyssen B, Naeyaert J-M, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. ANNALS OF THE RHEUMATIC DISEASES. LONDON: B M J PUBLISHING GROUP; 2010;69(1):193–7.
MLA
SMITH, VANESSA, JENS VAN PRAET, BERNARD VANDOOREN, et al. “Rituximab in Diffuse Cutaneous Systemic Sclerosis: An Open-label Clinical and Histopathological Study.” ANNALS OF THE RHEUMATIC DISEASES 69.1 (2010): 193–197. Print.